COMMUNIQUÉS West-GlobeNewswire

SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors
22/09/2026
New director brings nephrology development expertise and over 30 years of experience in the biopharmaceutical industry JERSEY CITY, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or [...]
Clene to Present at Upcoming Investor Conferences
22/09/2026
SALT LAKE CITY, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced that management will participate at the 5 th Annual ROTH Healthcare Opportunities Conference and at the Lytham Partners [...]
HepaRegeniX Completes Darizmetinib Treatment Phase for First Patient Undergoing Major Liver Resection in Phase 1b Liver Regeneration Study
22/09/2026
HepaRegeniX to seamlessly advance darizmetinib’s clinical development to Phase 2a following completion of the Phase 1b in 2026 Tuebingen, Germany, September 22, 2026 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage [...]
Transactions in connection with share buy-back program
22/09/2026
Company announcement no. 36 - 26 22 September 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Bavarian Nordic – Notification of Holding of Treasury Shares
22/09/2026
COPENHAGEN, Denmark, September 22, 2026 - Pursuant to Section 31 of the Danish Capital Markets Act, it is hereby announced that as of September 21, 2026, Bavarian Nordic’s holding of treasury shares amounted to 3,965, [...]
AstronauTx awarded research funding from The Michael J. Fox Foundation and Parkinson’s UK to explore sleep-based approaches for Parkinson's disease
22/09/2026
MJFF grant will support development of a potential disease-modifying treatment for prodromal Parkinson's disease by targeting restorative sleep mechanisms Parkinson's UK-funded research with University College London ( [...]
Dialybrid secures €15 million series A round and announces successful first-in-human implant of novel Silkothane® Arteriovenous Graft for vascular access in hemodialysis
22/09/2026
Silkothane® Arteriovenous Graft is a novel hybrid arteriovenous graft engineered to integrate into patients’ vessels and provide a safe, easy-to-cannulate, durable, vascular access for hemodialysis in patients with end- [...]
Opterion Health Announces Positive Phase 1 Results for OPT101, Supporting Advancement to Phase 2a
22/09/2026
SPARC study achieved all its objectives, establishing a strong clinical foundation for a differentiated, non-glucose-based treatment for peritoneal dialysis Positive Phase 1 results strengthen confidence in OPT101 , [...]
HighLife Raises $90+ Million to start its US Pivotal Study and accelerate Commercial Expansion in Europe
22/09/2026
Paris, France, September 22 – HighLife SAS, a MedTech company focused on transcatheter solutions for structural heart disease, today announced the successful completion of a $90+ Million (€80 Million) financing round . [...]
HighLife lève plus de 90 millions de dollars pour lancer son étude pivot aux États-Unis et accélérer son développement commercial en Europe
22/09/2026
Paris, France - le 22 septembre 2026 – HighLife SAS, Medtech spécialisée dans les solutions transcathéter destinées au traitement des maladies cardiaques structurelles, annonce aujourd’hui avoir réalisé avec succès une [...]
DXS INTERNATIONAL PLC (AQSE: DXSP) ANNUAL RESULTS FY 30 APRIL 2026
22/09/2026
The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union ( [...]
Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026
22/09/2026
Leniolisib was generally well-tolerated, with clinical improvements across multiple measures of immune dysregulation, including reductions in lymphoproliferation Separately, Pharming expects to report topline results [...]
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for dual GLP-1/GIP receptor agonist enicepatide in people living with type 2 diabetes and overweight or obesity
22/09/2026
At the highest dose (24 mg), enicepatide achieved a mean HbA1c reduction of 2.65% at 48 weeks, highlighting its potential for best-in-disease glycemic control In patients with poor baseline glycemic control (HbA1c >8 [...]
Respiree Extends Series A Syndicate with Addition of International Investors to Support Continued Global Growth
22/09/2026
HOUSTON and SINGAPORE, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Respiree , a health tech company developing artificial intelligence (AI) platforms to manage disease progression across the healthcare continuum, today announced [...]
His Choice Health Opens Richmond Vasectomy Clinic, Bringing Single-Visit Care to Virginia
22/09/2026
New Richmond location expands access to minimally invasive no-scalpel vasectomy with transparent pricing, single-visit scheduling and mail-in follow-up testing. Richmond, VA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- His [...]
Helus Pharma to Participate at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit
21/09/2026
CEO Michael Halstead to participate in a fireside chat on September 23, 2026 at 9:00 a.m. EDT NEW YORK and TORONTO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus [...]
Onco360® is a participating specialty pharmacy in the ZENBEXUS™ (iberdomide) limited dispense network
21/09/2026
LOUISVILLE, Ky., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Onco360 ® , the nation’s leading independent Specialty Pharmacy, has been selected as a participating pharmacy by Bristol-Myers Squibb for ZENBEXUS™ (iberdomide), [...]
TOMI Environmental Solutions Announces Mutual Termination of Merger Agreement with Carbonium Core
21/09/2026
FREDERICK, Md., Sept. 21, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. ® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, and Carbonium Core, Inc. (“Carbonium”), [...]
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference
21/09/2026
PONTE VEDRA, Fla., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan [...]

Pages

Other news

Promaxo Announces Closing of Series C Financing and $100M Credit Facility

Contenu:

The growth capital will expand manufacturing capacity, reduce backlog, and support new regulatory filings

ProKidney to Host Virtual KOL Event to Recap Mechanism of Action Data Presented at ASN Kidney Week and Provide a Corporate Update

Contenu:

WINSTON-SALEM, N.C., Oct. 22, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp.

BreathiZen Introduces BreathiZen Spray - A New Multi-Ingredient Dietary Supplement For Your Respiratory Wellness

Contenu:

BreathiZen is a once-daily oral spray that brings together botanical extracts, an enzyme preparation, and selected nutrients in a 60 ml bottle designed to fit easily into an adult wellness routine.

New York, Oct. 22, 2026 (GLOBE NEWSWIRE) --

RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026

Contenu:

Company to host conference call on November 5, 2026, at 4:30 p.m. ET

BridgeBio to Report Third Quarter 2026 Financial Results and Commercial Updates on October 29, 2026 at 4:30 pm ET

Contenu:

PALO ALTO, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc.

Ernexa Therapeutics Highlights ERNA-101’s Path Toward the Clinic and Differentiated Cell Therapy Platform in New “What This Means” Segment

Contenu:

Leadership discusses recent FDA engagement, the technology underlying ERNA-101 and the development strategy supporting planned first-in-human clinical evaluation

SciSparc: Subsidiary NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome

Contenu:

TEL AVIV, Israel, Oct. 22, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its subsidiary, NeuroThera Labs Inc.